Former Senior Vice President, Chief Financial Officer, Corporate Strategy Officer at Alcon, Inc.
Richard Croarkin has served as a member of our Board since May 2015. Mr. Croarkin previously served as Chief Financial Officer of Nestle Health Science, a division of Nestle focused on medicalized nutrition solutions for chronic medical conditions from December 2010 to February 2013. During his tenure, he was responsible for financial strategy in support of the R&D pipeline, including multiple transactions ranging from minority stakes and joint ventures, to outright acquisitions. Prior to this, Mr. Croarkin was Senior Vice President, Chief Financial Officer, and Corporate Strategy Officer at Alcon, which had annual sales of $7.1 billion and was the world’s leading ophthalmic pharmaceutical and medical device company before its acquisition by Novartis for $50 billion. Previously, he was Executive Vice President and Chief Financial Officer of Nestle Waters North America, overseeing the finances of a business unit that grew to $4.4 billion in sales. Before joining Nestle, Mr. Croarkin worked for PepsiCo, Inc., where he served in a number of senior financial positions around the world, including as Chief Financial Officer of Pepsi Latin America and Pepsi Canada. He started his career with AMAX, Inc., where he worked in treasury, corporate development, and planning. Mr. Croarkin was a Director on the Supervisory Board of the German publicly traded company, WaveLight A.G., which manufactures and globally markets laser and diagnostic systems for refractive eye surgery. Mr. Croarkin currently serves as a member of the board of directors of Clearside Biomedical, a company advancing eye disease therapies by delivering drugs to the suprachoroidal space via a proprietary microinjector. He also serves on occasion as a panelist on the NASDAQ Listing Qualifications Panel. Mr. Croarkin received his B.A. degree in economics from Georgetown University and his MBA in finance from the University of Connecticut.
Mechiel (Michael) M. du Toit
Chief Growth Officer for Publicis Health
Mechiel (Michael) M. du Toit has served as a member of our Board since June 2015. In December 2017, Mr. du Toit was appointed Chief Growth Officer of Publicis Health, a division of Publicis Groupe, S.A., the third largest advertising and media company in the world. He previously served as President of Everyday Health since February 2015. Prior to this, Mr. du Toit served in various positions, including Global Group President, at Publicis Healthcare Communications Group from March 2012 to February 2015. He held various senior executive positions from July 2006 to February 2012 at other companies, including President of Digitas Health where he was a founding member, Digitas Health Media, and RazorFish Health. Mr. du Toit also has held executive roles at premier marketing agencies including Grey Advertising, BBDO, and inVentiv Health Communications. He also held senior marketing positions at pharmaceutical companies such as GlaxoSmithKline and Boehringer Ingelheim Pharmaceuticals. At Glaxo, as Vice President of Marketing, he launched several blockbuster pharmaceutical products, including Serevent® (salmeterol) and Flonase® (fluticasone nasal). Mr. du Toit previously served as a member of the National Pharmaceutical Council, Pharmaceutical Advertising Council, Advertising Club of Fairfield, Advertising Club of New York, Editorial Board of Medical Marketing and Media, Prescription Drug Advertising Coalition, and Triangle Advertising Federation. He started his career at Unilever, a consumer products company. He received his B.S. in Economics and Marketing from Stellenbosch University in South Africa.
DAVID W. GRYSKA
Former Chief Financial Officer and Executive Vice President at Incyte Corp, and Chair of the Audit Committee
David W. Gryska rejoined our Board in September 2018, after serving as a member from May 2012 through May 2015. Mr. Gryska retired from Incyte Corp., where he was Chief Financial Officer and Executive Vice President, at the end of 2018. He currently serves on the Board of Directors of Seattle Genetics, Inc. and PDL BioPharma, Inc. Mr. Gryska has spent over 20 years as a senior executive at life science and biotechnology companies with extensive experience relating to financings, acquisitions, global expansion and strategic transactions. Prior to joining Incyte Corp., he held positions including President, CEO, COO and Director at Myrexis, Inc., Chief Financial Officer and Senior Vice President at Celgene Corp., and Chief Financial Officer and Senior Vice President at Scios, Inc. Mr. Gryska holds a BA in Accounting and Finance from Loyola University in Chicago and an MBA from Golden Gate University.
- Chair of the Audit Committee
Peter J. McDonnell, M.D.
William Holland Wilmer Professor of Ophthalmology and Director of the Wilmer Eye Institute at the Johns Hopkins University School of Medicine
Peter J. McDonnell, M.D. has served as a member of our Board since June 2020. Since 2003, Dr. McDonnell has served as the William Holland Wilmer Professor of Ophthalmology and Director of the Wilmer Eye Institute at the Johns Hopkins University School of Medicine. Prior to this, in 1999, he was the named the Irving H. Leopold Professor and Chair of the Department of Ophthalmology at the University of California-Irvine. From 1987 to 1988, Dr. McDonnell served as the Assistant Chief of Service at the Wilmer Institute. From 1988 to 1999, he served as a full-time faculty at the University of Southern California, where he advanced to the rank of professor in 1994. Dr. McDonnell has published over 250 scientific articles and holds ten patents. He has been the Chief Medical Editor of Ophthalmology Times since 2004 and has also served on the editorial boards of numerous ophthalmology journals. He also serves as the Immediate Past President and director of the National Alliance for Eye and Vision Research and the Alliance for Eye and Vision Research and is Vice President of the Pan-American Ophthalmological Association. Dr. McDonnell received his bachelor’s in chemistry from Dartmouth College and his M.D. from the Johns Hopkins University School of Medicine. He completed a residency in ophthalmology at the Wilmer Institute, followed by a fellowship in Cornea and External Diseases at the Doheny Eye Institute of the University of Southern California.
Former Chief Operating Officer for Endo Health Solutions, Inc.
Julie McHugh has served as a member of our Board since June 2015. Ms. McHugh served as Chief Operating Officer of Endo Health Solutions, Inc., from March 2010 until her retirement in May 2013, where she was responsible for the specialty pharmaceutical and generic drug businesses. Prior to this, Ms. McHugh was CEO of Nora Therapeutics, Inc., a venture capital–backed biotech start-up company focused on developing novel therapies for the treatment of infertility disorders. Previously, she served as company group Chairman for Johnson & Johnson’s worldwide virology business unit, and prior to this, she was president of Centocor, Inc., a J&J subsidiary. In this role, Ms. McHugh oversaw the development and launches of several products, including Remicade® (infliximab), Prezista® (darunavir), and Intelence® (etravirine). Prior to joining Centocor, Ms. McHugh led marketing communications for the gastrointestinal drug Prilosec® (omeprazole) at Astra-Merck, Inc. She currently serves on the Board of Directors of Ironwood Pharmaceuticals, Inc., Lantheus Holdings, Inc., New Xellia Group A/S, Trevena Pharmaceuticals, Inc., and she previously served on the Board of Directors of the Biotechnology Industry Organization (BIO), the New England Healthcare Institute (NEHI), the Pennsylvania Biotechnology Association, and ViroPharma Inc. Ms. McHugh received her M.B.A. from St. Joseph’s University and her B.S. from Pennsylvania State University.
*Lead Independent Director